Pharma-free CME gets sharp response

Share this article:

ACCME was surprised by the vociferous response to its June 11 call for comment on several proposals, including one that would establish a "pharma-free" label for accredited CME and another that would designate activities to be free of teachers or authors that did promotional work. Also included was a proposal to establish an independent funding mechanism for CME. 
"

They were diverse, they covered a wide range of opinion," said ACCME chief executive Murray Kopelow, MD.


In its response, the Society for Academic Continuing Medical Education (SACME) said a survey of its members found 76% opposed the creation of a commercial support free designation and 66% opposed the promotional teacher/author free label. "There should be one standard for CME accreditation," said SACME. "Creating a system where there are two categories has the potential to create the impression that commercially-supported CME is somehow inferior to that receiving no commercial support. As such, it would then inappropriately imply that commercially-supported CME is biased."


"Three-quarters of our membership felt that this wasn't a good idea, and I think for many, it sets up an inherent dynamic that says one is more preferable to another," said Lois Colburn, president of SACME and executive director at the University of Nebraska Medical Center's continuing education program.


On promotional teacher and author-free CME, Kopelow said: "The CME system feels strongly that the ACCME Standards for Commercial Support manage the boundary issues between commercial supporters and the CME industry, that they've been doing it for two decades, that they...should continue to do it and that it's up to the accredited providers to meet the expectations of the Standards for Commercial Support and it's up to the ACCME to monitor those boundaries. It was clear those people believe that should be what happens in the future."

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.